Reviewed by Michael Gill, B. Sc.
1 Carfilzomib Clinical Trials Near Me
Top Cities for Carfilzomib Clinical Trials
Image of Chicago in Illinois.
1Active Trials
University of ChicagoTop Active Site
Image of Detroit in Michigan.
1Active Trials
Wayne State University - Karmanos Cacner InstituteTop Active Site
Carfilzomib Clinical Trials by Phase of Trial
Phase 3 Carfilzomib Clinical Trials
1Active Carfilzomib Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Most Recent Carfilzomib Clinical Trials
Clinical Trial
Began Recruiting Date

What Are Carfilzomib Clinical Trials?

Carfilzomib is an active ingredient found in drugs used to treat multiple myeloma.

Multiple myeloma is a type of cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The abnormal cells produce proteins that prevent the normal development of blood cells in the body. The condition at present is untreatable, with approximately 46% of patients dying within five years of diagnosis. But research is progressing to find a drug regimen that will either stop or slow down the progression of multiple myeloma in patients.

Why Is Carfilzomib Being Studied In Clinical Trials?

Carfilzomib is a proteasome inhibitor drug that the FDA approved for treating multiple myeloma. It has been used in treating newly diagnosed patients and those who have relapsed or are diagnosed with refractory multiple myeloma.

The primary aim of the research is to compare the progression-free survival rate between patients given Carfilzomib, lenalidomide, and dexamethasone and those given lenalidomide alone. Other objectives include determining the overall response rate associated with the treatment combination of Carfilzomib, lenalidomide, and dexamethasone.

How Does Carfilzomib Treatment Work?

Carfilzomib targets proteasome enzymes. By irreversibly binding to the binding sites, it inhibits the action of these enzymes, thereby reducing their growth and inducing the death of the malignant plasma cells.

The drug has shown positive results, improved survival outcomes, and minimal patient safety risks. Although the treatment prolonged patients' lives by months rather than years, it can be viewed positively because multiple myeloma is difficult to treat with a low overall survival rate.

What Are Some of the Breakthrough Clinical Trials Involving Carfilzomib?

There have been several landmark studies involving Carilzomib in recent years. Some of the most notable studies are:

2019: Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update? - the study found that Carfilzomib is an important drug for treating multiple myeloma patients. The drug has substantial efficacy and good tolerability for patients. It can be used as part of combination therapy in varied patient populations.

2012: A phase 1/2 study of Carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma - the study found that when a combination of lenalidomide, dexamethasone, and Carfilzomib was administered to newly diagnosed patients with multiple myeloma, the 24-month progression-free survival was 92% among the studied population.

Who Are The Key Opinion Leaders On Carfilzomib Clinical Trial Research?

Professor Andrzej Jakubowiak, MD, PhD

Andrzej Jakubowiak is a professor at the University of Chicago. He has published extensively in the field of anti-cancer therapy.

Rafael Fonseca, M.D

Rafael Fonesca is a hematologist specializing in the care and research of multiple myeloma and related conditions. Dr. Fonseca graduated from Universidad Anahuac, Mexico. He completed an Internal Medicine internship at the University of Miami, Florida, and a fellowship in hematology and oncology at Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota. He has achieved the academic distinction of Mayo Clinic Distinguished Investigator.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: October 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.